SUPN
Supernus Pharmaceuticals Inc

2,383
Mkt Cap
$2.62B
Volume
744,186.00
52W High
$57.65
52W Low
$29.16
PE Ratio
-134.10
SUPN Fundamentals
Price
$44.79
Prev Close
$45.70
Open
$46.23
50D MA
$48.54
Beta
0.51
Avg. Volume
795,575.09
EPS (Annual)
$1.32
P/B
2.49
Rev/Employee
$981,924.33
Loading...
Loading...
News
all
press releases
Connor Clark & Lunn Investment Management Ltd. Sells 49,466 Shares of Supernus Pharmaceuticals, Inc. $SUPN
Connor Clark & Lunn Investment Management Ltd. trimmed its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 28.7% during the second quarter, according to the company...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded by Wall Street Zen to Strong-Buy Rating
Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday...
MarketBeat·11d ago
News Placeholder
Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Down - Should You Sell?
Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Down - Time to Sell...
MarketBeat·14d ago
News Placeholder
Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks·16d ago
News Placeholder
Supernus Pharmaceuticals (SUPN) Surpasses Q3 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of +23.17% and +5.52%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·16d ago
News Placeholder
BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View
Biogen's Q3 earnings and sales top estimates on strong drug demand, but shares slide after the company cuts its 2025 EPS forecast.
Zacks·21d ago
News Placeholder
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·21d ago
News Placeholder
BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -7.95% and +14.44%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·22d ago
News Placeholder
Here's Why Supernus Pharmaceuticals (SUPN) is a Great Momentum Stock to Buy
Does Supernus Pharmaceuticals (SUPN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·22d ago
News Placeholder
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·23d ago

Latest SUPN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.